1-2 of 2 results for subject:Pfizer
Librarians' tools
- Search time
- 0.155 seconds
- Solr query time
- 0.002 seconds
- Search query
- subject:Pfizer
- We searched for
- subject_t:Pfizer OR subject_ses:61578
Type
House
Session
Year
Department
Member
Primary member
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the potential implications for her policies of the article in the British Medical Journal entitled Pfizer-BioNTech vaccine is “likely” responsible for deaths of some elderly patients, Norwegian review finds, published on 27...
To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the potential implications for her policies of the article in the British Medical Journal entitled Pfizer-BioNTech vaccine is “likely” responsible for deaths of some elderly patients, Norwegian review finds, published on 27...
Following the initial roll out of the COVID-19 vaccination programme in December 2020, the Medicines and Healthcare products Regulatory Agency (MHRA) had a comprehensive surveillance strategy in place, enabling continual close monitoring of emerging safety evidence including studies, published literature, and data arising from the widespread use in the United Kingdom and globally. This included the article and Norwegian reports highlighted. The MHRA communicates safety advice based upon consideration of the totality of evidence from all relevant information sources, rather than the strengths and limitations of individual data sources.
To ask the Secretary of State for Health and Social Care, whether he has plans to expand the eligibility criteria for the Pfizer Covid-19 vaccine; and what guidance his Department has issued on the additional protection provided by additional doses and any related health implications.
To ask the Secretary of State for Health and Social Care, whether he has plans to expand the eligibility criteria for the Pfizer Covid-19 vaccine; and what guidance his Department has issued on the additional protection provided by additional doses and any related health implications.
The primary aim of the COVID-19 vaccination programme continues to be the prevention of severe disease, namely hospitalisation and death, arising from COVID-19. The Joint Committee on Vaccination and Immunisation (JCVI) has recommended a targeted approach to COVID-19 vaccination focussed on those most vulnerable from COVID-19, including older individuals and individuals with specified existing clinical conditions.
On 8 August 2023, the Government accepted advice from the JCVI on who should be offered a COVID-19 vaccine in the autumn 2023 booster programme. This includes residents in a care home for older adults, all adults aged 65 years old and over, persons aged six months to 64 years old in a clinical risk group, frontline health and social care workers, persons aged 12 to 64 years old who are household contacts and persons aged 16 to 64 years old who are carers. For the autumn 2023 campaign, the JCVI have advised the Pfizer-BioNTech mRNA monovalent XBB vaccine for use in individuals from six months old and the Pfizer-BioNTech mRNA (Comirnaty) bivalent Original/Omicron BA.4-5 vaccine for use in individuals aged 12 years old and over. All individuals who are currently eligible for COVID-19 vaccination are therefore eligible to receive a Pfizer COVID-19 vaccine. There are no plans to expand the eligibility criteria for the autumn campaign. The JCVI will continue to review evidence and will provide further advice regarding future vaccination programmes in due course.
The JCVI has advised that further vaccination doses provide additional protection from serious outcomes from COVID-19. Whilst natural immunity alone provides good levels of protection against severe COVID-19, the combination of natural and vaccine-induced immunity, also known as hybrid immunity, is associated with even higher levels of protection.